BioPharm News

Feb 12, 2008
BioPharm International
By BioPharm International Editors
The US FDA has requested nearly $2.4 billion for its fiscal 2009 budget, a 5.7% increase over the budget that FDA received for the current fiscal year.
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Laureate Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal transduction antibody program.
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Venture capitalists will largely direct their investments to the greentech and biotech industries in the coming year, while China and India remain hot destinations for venture funds, according to a recent survey by the auditing firm KPMG.
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Robert F. Friel has been elected chief executive officer of PerkinElmer, Inc. (Waltham, MA).
Feb 12, 2008
BioPharm International
By BioPharm International Editors
A public database of extractables and leachables data would save time, effort, and costs during drug development, agreed participants at the CMC Strategy Forum on Extractables and Leachables on January 27.
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Eli Lilly and Company (Indianapolis, IN) has completed its licensing and development agreement with BioMS Medical Corp. (Edmonton, Alberta, Canada).
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Cobra Biomanufacturing Plc (Keele, UK) has entered into a manufacturing development agreement with GenVec, Inc. (Gaithersburg, MD) for TNFerade.
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Novartis Vaccines and Diagnostics (Marburg, Germany) received a warning letter on January 24, 2008, citing significant deviations from current good manufacturing practices (cGMP) in the manufacture of its rabies vaccine (RabAvert) and diphtheria and tetanus toxoids adsorbed concentrate (without preservative), with regard to bulk lot production and process controls and investigations.
Feb 12, 2008
BioPharm International
By BioPharm International Editors
Polyplus-transfection (New York, NY), has announced the production of its transfection reagent in vivo-jetPEI, manufactured in full compliance with good manufacturing practices (GMPs).
Feb 11, 2008
By BioPharm International Editors
Novartis Vaccines and Diagnostics (Marburg, Germany) received a warning letter on January 24, 2008, citing significant deviations from current good manufacturing practices.
native1_300x100
lorem ipsum